Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 1999

View Archived Issues

New data presented on Pentose's product for viral inactivation of blood components

Allergan establishes agreement with 3M for Tazorac

Vical's cancer gene therapies profiled at chemotherapy meeting

BMS seeks approval in U.S. for Glucophage XR tablets

Potent, selective and stable tryptase inhibitors developed at Protherics

Banyu/Merck team reports discovery of the first selective small-molecule ORL1 antagonist

Anthranilic acid derivatives from Fujisawa particularly useful for erectile dysfunction

RPR's new cell adhesion inhibitors especially useful for asthma, joint inflammation and IBD

Active Biotech presents novel agents for MS

Collateral Therapeutics succeeds in developing a double-barreled gene therapy for CV disease

Korean researchers report development of potent angiotensin II antagonists

Potent and selective anti-HIV agents patented by French investigators

Korean researchers describe efforts to develop colon-specific 5-FU prodrug

Dual NK1/NK2 antagonist examined for disposition in rats

LMW amido acid favorably influences PK/PD of porcine insulin delivered to the lungs

Sepracor and Abbott to copromote Xopenex in the U.S.

AxyS Pharmaceuticals amends CNS genomics agreement with Parke-Davis

Soft analogues of amiodarone with rapid, short-lasting antiarrhythmic effects

Launch imminent for Fujisawa's new treatment of atopic dermatitis

Prodrugs of AZT monophosphate evaluated for in vitro transepithelial transport, metabolism

Ivax and BMS establish collaboration agreement in oncology, respiratory fields

Phase I clinical trial initiated with Xcytrin for treatment of childhood gliomas

OC144-093: clinical pharmacokinetics and safety after i.v. and oral dosing

Minnesota academics develop novel strategy for treating pain

Vion makes significant progress during third quarter

1999 AAPS news: Lilly studies PK interactions between LY-335979 and doxorubicin in patients

PEG-Intron submitted for marketing approval in Europe

Combination with probenecid may minimize risk of renal toxicity for licostinel

Taro's novel anticonvulsant cleared for Canadian clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...